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ABSTRACT 
Gemcitabine (Gem) is used as a single agent or in combination with other anticancer agents to treat many types of 
solid tumors. However, it has many limitations such as a short plasma half-life, dose-limiting toxicities and drug 
resistance. Cell-penetrating peptides (CPPs) are short peptides which may deliver a large variety of cargo mole-
cules into the cancerous cells. The current study was designed to evaluate the antiproliferative activity of gemcita-
bine chemically conjugated to CPPs. The peptides were synthesized using solid phase synthesis procedure. The 
uptake efficiency of CPPs into cells was examined by flow cytometry and fluorescent microscopy. The synthesized 
peptides were chemically conjugated to Gem and the in vitro cytotoxicity of conjugates was tested by MTT assay 
on A594 cell line. According to the obtained results, cellular uptake was increased with increasing the concentra-
tion of CPPs. On the other hand the coupling of Gem with peptides containing block sequence of arginine 
(R5W3R4) and some alternating sequences (i.e. [RW]6 and [RW]3) exhibited improved antitumor activity of the 
drug. The findings in this study support the advantages of using cell-penetrating peptides for improving intracel-
lular delivery of Gem into tumor as well as its activity. 
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INTRODUCTION 
Gemcitabine (Gem), a deoxycytidine ana-
log, is used in the treatment of many types of 
solid tumors, including pancreatic, ovarian, 
breast, bladder, and lung cancers (Tao et al., 
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2012; Martin-Banderas et al., 2013). For acti-
vation this pro-drug requires cellular uptake 
and intracellular phosphorylation (Fujimura 
et al., 2014). Inside the cell, gemcitabine is 
phosphorylated to gemcitabine monophos-
phate (dFdCMP) by deoxycytidine kinase 
(dCK), which is further phosphorylated to di- 
and tri-phosphorylated gemcitabine (dFdCDP 
and dFdCTP) (Derakhshandeh and Fathi, 
2012; Lansakara et al., 2012). The metabolite, 
dFdCTP, is incorporated into DNA as a false 
nucleoside, eventually leading to inhibition of 
DNA polymerases, and induces cells to un-
dergo apoptosis (Vandana and Sahoo, 2010; 
Chung et al., 2012). Although the molecular 
events mentioned above eventually contribute 
to the effectiveness of gemcitabine in fighting 
tumor cells, however the drug possesses cer-
tain demerits. Gemcitabine is converted into 
its inactive and more soluble metabolites, 2’, 
2’-difluorodeoxyuridine (dFdU) via deox-
ycytidine deaminase expressed in blood and 
various tumor tissues, causing a very short 
plasma half-life (Vandana and Sahoo, 2010; 
Dalla Pozza et al., 2013). Thus, a frequent ad-
ministration schedule at high doses is re-
quired, leading to significant side effects such 
as hepatotoxicity and nephrotoxicity (Das et 
al., 2014). Additionally, gemcitabine is too 
hydrophilic to passively cross the plasma 
membrane and its cellular uptake requires the 
presence of nucleoside transport proteins such 
as human equilibrative nucleoside trans-
porter-1 (hENT1) (Bildstein et al., 2010). 
Therefore, drug resistance associated with de-
ficiencies in the expression of hENT1 confers 
lower gemcitabine toxicity in tumor cells by 
blocking the cellular transport of gemcitabine 
(Chung et al., 2012; Tao et al., 2012).  
Up to now various delivery strategies such 
as liposomes (Grazia Calvagno et al., 2007; 
May et al., 2013; Bersani et al., 2014), nano-
particles (Lee et al., 2013; Dolatabadi et al., 
2015), lipidic and nonlipidic derivatives (Ber-
sani et al., 2014), PEG and other polymeric 
drug conjugates (Aggarwal et al., 2013; Chit-
kara et al., 2013) have been investigated to 
prevent rapid plasma degradation and to im-
prove delivery of gemcitabine to the tumor 
tissue. However, gemcitabine is a low molec-
ular weight compound with high water solu-
bility. At physiological pH it is mainly un-
charged which may readily diffused out from 
the liposomal bilayers and nanoparticles re-
sulting in low drug encapsulation efficiencies 
and rapid release rate (Chitkara et al., 2013). 
Among the new strategies, the pro-drug ap-
proach has gained major interest which in-
cludes modifications on gemcitabine mole-
cule and conjugation onto a lipoid or poly-
meric carrier (Chitkara et al., 2013). How-
ever, the delivery of hydrophilic compounds 
by these carriers into cells is limited by their 
poor ability to penetrate through cell mem-
brane. Therefore an alternative strategy, 
which has recently attracted much more atten-
tion, was established by chemically conjugat-
ing hydrophilic drugs to cell-penetrating pep-
tides (CPPs). 
PPs are short peptides which are able to 
deliver a large variety of cargo molecules into 
a wide range of cells and tissues in a nontoxic 
manner (Cohen-Avrahami et al., 2010; Liu et 
al., 2013; Sawant et al., 2013; Copolovici et 
al., 2014; Ren et al., 2014). It has been 
demonstrated that conjugation of gemcitabine 
with polypeptide may improve its plasma sta-
bility and sustain the drug release profile 
(Kiew et al., 2010). In recent years, numerous 
natural and synthetic CPPs, such as Tat, trans-
portan, and polyamino acids (e.g., poly-ar-
ginines), were discovered or designed for in-
tracellular delivery of anticancer agents 
(Gupta et al., 2011; Nasrolahi Shirazi et al., 
2013a). Among these CPPs, TAT peptide and 
poly-arginine are the most frequently used for 
the delivery of various molecules such as pro-
teins, peptides, RNA, therapeutic and imaging 
compounds into cells (Shirazi et al., 2014; 
Tsumuraya and Matsushita, 2014). It has been 
shown that long poly-arginine generally re-
sults in more effective uptake, but the major-
ity of studies suggest optimal lengths in the 
range of 8 to 15 arginines. Recently, it was re-
vealed that the presence of tryptophan and 
backbone spacing can affect uptake efficiency 
as well as its mechanism (Rydberg et al., 
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2012). Several small molecule chemothera-
peutics, such as Taxol (Dubikovskaya et al., 
2008), methotrexate (Lindgren et al., 2006), 
and doxorubicin (Nasrolahi Shirazi et al., 
2013b) have shown improved activity when 
conjugated with CPPs. 
The objective of this study was to exam-
ine the effect of gemcitabine coupling with ar-
ginine and tryptophan-rich CPPs on the tox-
icity of the drug in A549 cell line. Further-
more, intracellular uptake, and subcellular 
distribution of five synthesized CPPs were 
studied.  
 
MATERIALS AND METHODS 
Materials 
Gemcitabine hydrochloride was pur-
chased from Actavis (Italy). FMOC-Rink-
Amide AM resin and amino acid derivatives 
were obtained from AAPPTec (Louisville, 
USA). Coupling agents (TBTU, DIEPA), 
scavengers (ethanedithiol, phenol, TIPS), 
cleavage reagents (piperidine, TFA), and 
FITC were purchased from Sigma (St. Louis, 
USA). 3-(4,5-dimethylthiazol-2-yl) -2,5-di-
phenyltetrazolium bromide (MTT), 
RPMI1640, fetal bovine serum (FBS), tryp-
sin-EDTA and penicillin/streptomycin were 
purchased from Invitrogen (Carlsbad, USA).  
 
Peptide synthesis 
All peptides were synthesized manually 
by solid-phase peptide synthesis method on 
Rink-Amide AM resin by FMOC strategy in 
a fritted glass vessel (Mohammadi et al., 
2015; Shirani et al., 2015). The resin was 
swelled in anhydrous DMF for about 1 h un-
der dry nitrogen. FMOC deprotection of resin 
was carried out using piperidine in DMF 
(20 % v/v, 2 ml, 30 min). FMOC-Arg (Pbf) -
OH (0.14 mmol) was coupled to the resin in 
the presence of TBTU (0.12 mmol) and DI-
PEA (50 μL) in DMF (2 ml) by mixing for 
2 h. After completion of the coupling, the re-
action solution was filtered off and the resin 
was washed with DMF (4 × 2 ml) and DCM 
(4 × 2 ml), followed by FMOC deprotection 
using piperidine in DMF. The resin was 
washed with DMF and DCM. Ninhydrin test 
was used to monitor FMOC deprotection and 
coupling of amino acids in each step. After 
the coupling of all amino acids, the resin was 
washed with DMF, DCM and ethanol (each 2 
× 2 ml). The resin was dried under vacuum for 
24 h. Fresh cleavage cocktail, reagent B, 
TFA/ TIPS / phenol /water (88:2:5:5 v/v/v/v, 
3 ml), was added to the resin for side-chain 
deprotection and the final cleavage of the syn-
thesized peptide from the solid support. The 
mixture was shaken at room temperature for 
2 h. The resin was collected by filtration and 
washed with another 2 ml of fresh cleavage 
cocktail. Combined filtrates were evaporated 
to reduce the volume under dry nitrogen. The 
crude peptide was precipitated by adding 
100 ml of diethyl ether and centrifuged at 
4000 RPM for 5 min to obtain the solid pre-
cipitates. The obtained peptide was further 
washed with ether (2 ×50 ml) for 2 times and 
lyophilized (Table 1, Figure 1). 
 
Table 1: Peptide sequences 
Peptide Sequence 
[RW]3 RWRWRW 
[RW]4 RWRWRWRW 
[RW]5 RWRWRWRWRW 
[RW]6 RWRWRWRWRWRW 
R5W3R4 RRRRRWWWRRRR 
 
 
FITC labeling of peptides 
N-terminal FMOC deprotection of each 
prepared peptide was carried out using piper-
idine in DMF. A solution of 1.1 equivalent of 
FITC in pyridine/DMF/DCM was prepared 
and added to the peptide-resin then mixed 
overnight. The completion of the reaction was 
checked using ninhydrin test. The resin was 
washed and final cleavage of the CPP-FITC 
conjugates from the resin was carried out ac-
cording to the mentioned protocol.  
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Figure 1: Schematic representing synthesis of R5W3R4 peptide 
 
 
Preparation of drug-peptide conjugates  
Gemcitabine was coupled to peptides us-
ing a succinyl spacer by linking the amine 
group of the peptide to the hydroxyl group of 
the drug. The NH2 group of the peptide was 
changed to a carboxyl moiety by reaction with 
succinic anhydride as a linker. After synthesis 
of peptides on the resin, deprotected peptides 
were treated with succinic anhydride (1.5 eq.) 
and DIEPA (3 eq) in DMF for 2 h. The com-
pletion of the reaction was controlled by nin-
hydrin test. The resin was washed with DMF 
(4 × 2 ml) and DCM (4 × 2 ml). For conjuga-
tion of peptides to gemcitabine, TEA (50 µl) 
and DIEPA (3 eq) were added to a solution of 
40 mg of gemcitabine in 3 ml of 85:15 (v/v) 
DMA/DMF mixture and was added to the 
succinylated peptide. The reaction mixture 
was kept under gentle stirring for 48 h. The 
mixture was then dried and drug-peptide con-
jugates were cleaved from the resin with 
TFA/ TIPS / phenol /water (88:2:5:5 v/v/v/v, 
3 ml) cocktail (Figure 2). 
 
Cell culture 
A549 lung carcinoma cell line was ob-
tained from the Pasteur Institute (Iran). Cells 
were maintained in RPMI 1640 medium sup-
plemented with 10 % FBS, 100 units/ml pen-
icillin, and 100 μg/ml streptomycin and 
grown at 37 °C in a 5 % CO2 humidified at-
mosphere. 
 
In vitro cytotoxicity  
A549 cells were seeded into 96-well 
plates at a density of 1.5 × 104 cells/well and 
pre-incubated for 24 h. The next day, different 
concentrations of peptides were added to the 
culture medium. Cells were incubated at 
37 °C for 72 h. The medium was removed and 
the wells were washed with PBS. The MTT 
assay was performed by introducing 50 μl of 
2 mg/ml MTT to each well for 4 h. The cul-
ture media aspirated and then resulting form-
azan crystals were dissolved in DMSO and 
the absorbance of individual wells was ob-
tained at 570 nm. Untreated cells were de-
fined as 100 % viable. 
 
Fluorescent microscopy  
The cellular uptake of the FITC-labeled 
peptide was examined in A549 cell line. 
A549 cells were seeded with RPMI 1640 me-
dium on coverslips in 6-well plates and al-
lowed to adhere overnight. Then the medium 
was removed and washed with PBS. The cells 
were treated with FITC-labeled peptide for  
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Figure 2: Schematic representing preparing of gemcitabine-R5W3R4 conjugate 
 
 
1.5 h at 37 °C. After incubation, the media 
containing the compound were removed and 
the cells were washed with PBS three times. 
Coverslips were placed on a microscope slide 
(Olympus IX81 fluorescence microscope, 
Olympus Optical Co., Ltd., Tokyo, Japan). 
 
Flow cytometry 
A549 cells were seeded with RMPI 1640 
medium in 6-well plates (3×105 cells/well) 
24 h prior to the experiment. After 24 h, the 
medium was removed and washed with PBS. 
Then FITC-labeled peptide was added to the 
cells. The plates were incubated for 1.5 h at 
37 °C. After that, the medium containing the 
peptide was removed. The cells were washed 
three times with PBS and detached with 
0.25 % trypsin/EDTA (0.53 mM) for 5 min. 
To each well, 2 ml of the medium was added 
and centrifuged for 4 min. Cells were washed 
twice with PBS and finally were re-suspended 
in flow cytometry buffer and analyzed by 
FACSCalibur (Becton Dickinson, San Jose, 
CA, USA). 
RESULTS 
Synthesis of CPPs and preparing drug-CPP 
conjugates 
FMOC solid-phase peptide synthesis on 
the Rink-Amide AM resin was used for syn-
thesizing linear peptides R5W3R4, [RW]3, 
[RW]4, [RW]5, and [RW]6 with hydrophobic 
(W) and charged (R) residues. FITC was cou-
pled to synthesized peptides to investigate 
their uptake efficiency. Drug-CPP conjugates 
were prepared by using succinic linker. UV-
Vis spectroscopy was used for controlling the 
drug loading to peptides.  
 
Cellular toxicity of the CPPs 
As a functional delivery vector of anti-
cancer drugs, blank CPPs must have high up-
take efficiency with low levels of toxicity 
against cells (Soler et al., 2014). Therefore, all 
peptides were examined for their toxicity in 
A549 cells before examining the cellular tox-
icity of drug-CPP conjugates. The cytotoxi-
city was determined by MTT assay after 72 h 
of peptide exposure in concentration range 
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between 5 to 50 µM. As shown in Figure 3, 
the peptides exhibited no toxicity up to the 
concentration of 10 µM. Among five CPPs, 
[RW]4 and [RW]3 did not show toxicity even 
at 50 µM. However, R5W3R4 and [RW]6 ex-
hibited cell toxicity value of 9 % and 16 % at 
the concentration of 25 µM, respectively. At 
the concentration of 50 M, cell death caused 
by R5W3R4, [RW]6, and [RW]5 were 28 %, 
34 % and 14 % respectively. Thus, because of 
low toxicity, concentration of 25 μM was se-
lected for cell-based studies of drug-CPP con-
jugate.  
 
 
Figure 3: Cytotoxicity of peptides on A549 cells after 72 h incubation 
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Cellular uptake  
The uptake and intracellular localization 
of FITC-labeled peptides were examined by 
fluorescent microscopy. Figure 4 shows the 
intracellular distribution of the prepared pep-
tides following 1.5 h incubation. The uptake 
of all peptides was examined at the concentra-
tion of 25 µM. [RW]5 exhibited the lowest 
uptake into the cells among five peptides. Af-
ter entering the cell, much of [RW]5 accumu-
lated around the nucleus. R5W3R4, [RW]6 
and [RW]4 displayed homogeneous staining 
throughout the intracellular space. However, 
stronger intensity was observed in cellular 
structures that are morphologically identified 
as the cell nucleus and nucleoli. Fluorescent 
image revealed that [RW]3 enters mainly into 
the cell nucleus.  
Flow cytometry was used to determine the 
relative amounts of internalized peptide after 
1.5 h incubation at 37 °C. After the incuba-
tion, cells were treated with trypsin to remove 
the cell surface-bound peptides. Figure 5 
shows the relative fraction of positive cells 
(%) after treatment with peptides. The per-
centage of cell fluorescence was increased 
with increasing peptides concentration. This 
effect was nearly linear for the tested concen-
trations. There was an increase in fluores-
cence intensity of cells treated with peptides 
of higher amino acid content. However, the 
[RW]5 exhibited lower levels of intracellular 
fluorescence. R5W3R4 and [RW]3 with three 
tryptophan showed maximum intracellular 
fluorescence relative to other peptides.  
 
Antitumor performance of drug loaded 
CPPs 
The antitumor activity of free gemcitabine 
and its conjugates with CPPs (Gem–CPP) was 
investigated using MTT test after incubation 
for 72 h. The activity of drug-peptide conju-
gates i.e. Gem-R5W3R4, Gem-[RW]6, Gem-
[RW]5, Gem-[RW]4 and Gem-[WR]3, was 
evaluated and compared with that of the free 
drug (Figure 6). Drug loaded CPPs at concen-
trations less than 10 µM did not exhibit in-
creased anti-proliferative activity compared 
to the free drug. However, at 15 and 25 µM, 
Gem-R5W3R4, Gem-[RW]6 and Gem-
[WR]3 exhibited decreased cell viability. Free 
drug showed 20 % cell viability at concentra-
tions of 15 and 25 µM. The cell viability value 
was reduced to 16 % and 6 % with Gem-
R5W3R4 at 15 and 25 µM, respectively. In 
the case of Gem-[RW]6, cell viability was de-
creased to 14 % at 15 and 25 µM. Among the 
five peptide-drug conjugates, Gem-[RW]3 
displayed the highest cytotoxicity at 15 and 
25 µM. The cell viability of the drug was de-
creased to 9 % and 5 % when it was coupled 
to [RW]3 at 15 and 25 µM respectively. In the 
case of Gem-[RW]5 and Gem-[RW]4 conju-
gates, cell viability was slightly increased in 
comparison to the free Gem drug.  
The enhanced cell toxicity of drug-pep-
tide conjugates could be attributed to the high 
cellular uptake tendency of the prepared pep-
tides (Aroui et al., 2010) demonstrated by the 
flow cytometry and fluorescent microscopy 
studies (Figures 4 and 5).  
 
DISCUSSION 
Gemcitabine has a therapeutic activity 
against a variety of solid tumors (Chung et al., 
2012; Zhao et al., 2012). However, this anti-
cancer drug suffers from serious limitations. 
Gemcitabine has very short plasma circula-
tion time and high hydrophilicity, resulting in 
limited intracellular diffusion. In addition, 
cancer cells acquire resistance over time, 
which becomes a major concern for most 
gemcitabine-related chemotherapies (Maksi-
menko et al., 2013). The resistance of tumor 
is related to the mechanism of internalization 
of this drug. Transport of gemcitabine into the 
cell requires both the concentrative (hCNT) 
and equilibrative (hENT) nucleoside trans-
porters. Considering that cellular uptake of 
gemcitabine is mainly mediated by hENT1 
transporters, hENT1-deficient cells and de-
creased expression of hENT1 is accounted for 
decreased gemcitabine toxicity by blocking 
the cellular uptake of the drug (Pili et al., 
2010). Coupling of anticancer drug to CPP 
may result in numerous advantages, such as 
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Figure 4: Fluorescence microscopy, visualization of FITC-labeled, R5W3R4 (A, B), [RW]6 (C, D), [RW]5 
(E, F), [RW]4 (G, H), and [RW]3 (I, J) in A459 cells. The top photos show fluorescence microscopy and 
the bottom bright field of A459 cells. Live cells were treated with 25 µm of peptides for 1.5 h at 37 °C. 
Control cells were incubated in RPMI medium without the peptides.  
 
 
 
improved solubility, intracellular uptake, bio-
distribution and pharmacokinetic profiles. 
CPP-based drug delivery system offers great 
potential for improving intracellular delivery 
of therapeutic agents with poor permeability 
(Aroui et al., 2010; Cohen-Avrahami et al., 
2010; Huang et al., 2013; Liu et al., 2013; Ren 
et al., 2014). In this study, in order to protect 
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gemcitabine from rapid metabolic inactiva-
tion and to improve its cell penetration, some 
pro-drugs were designed by coupling gem-
citabine to CPP. This strategy could be used 
in fighting hENT1-deficient and resistant tu-
mor cells by increasing transport of the gem-
citabine into the cells. 
 
 
Figure 5: Cellular uptake of FITC-labeled pep-
tides in live A549 cells after incubation. The up-
take was measured as the relative fraction of pos-
itive cells (%) from flow cytometry analysis of all 
living cells positive for the fluorophore.  
 
 
After synthesis of peptides, the uptake ef-
ficiency was investigated. Then, gemcitabine 
was covalently attached to the peptides by us-
ing succinyl hydrolysable spacer which al-
lows for the drug release after uptake into the 
cells (Cavallaro et al., 2006). The cytotoxic 
efficacy of the free drug and drug-CPP conju-
gates was evaluated. The peptide sequences 
were chosen to examine how the presence of 
tryptophan and its position within the poly-ar-
ginine may influence the cellular uptake and 
cytotoxicity of the drug. It was evident that 
the addition of tryptophan to oligo-arginine 
could increase cellular uptake efficiency. Pep-
tides with tryptophans in the middle, or 
evenly distributed along the peptide sequence 
exhibited higher uptake. This observation was 
in consistency with earlier reports (Rydberg et 
al., 2012). By increasing the number of amino 
acids in the sequences the toxicity was im-
proved so that Gem-R5W3R4 and Gem-
[RW]6 conjugates with 12 residues exhibited 
the highest toxicity in cancer cells.  
The results showed that three of five pep-
tides improved cytotoxicity of gemcitabine. 
Gem-R5W3R4, Gem-[RW]6 and Gem-
[RW]3 conjugates displayed increased tox-
icity compared to free Gem. The increased 
toxicity of these drug-CPP conjugates was 
seen at 15 and 25 µm. One of the possible rea-
sons for this effect might be the mechanism of 
CPP cellular uptake. Recent studies showed 
that endocytic pathways are the major route 
for internalization of CPPs. Although the en-
docytosis pathway may be responsible for the 
vast majority of cationic peptide internaliza-
tion, numerous evidences suggest that direct 
penetration does occur at threshold concentra-
tions (Palm-Apergi et al., 2012). It was shown 
that at low concentration, endocytosis of pep-
tides could occur which may result in endoso-
mal entrapped peptides and possible meta-
bolic degradation (Mellert et al., 2012; Brock, 
2014). However at higher concentrations 
(above 10 µm), direct translocation into the 
cell is predominant. With the direct uptake, 
the drug molecules delivered by CPP would 
not fall into the endosome. Possibly, direct 
uptake of drug-CPP conjugates at higher con-
centrations is one of the reasons for increased 
toxicity of gemcitabine. In addition to im-
proved cytoplasmic delivery, it may also rep-
resent a valuable strategy to overcome drug 
resistance. The main mechanisms recognized 
for multidrug resistance is the presence of P-
glycoprotein in the plasma membrane, which 
can extrude a wide range of anticancer drugs. 
The ability of CPP-drug conjugates to evade 
the P-gp efflux pump was confirmed using 
several assays (Castex et al., 2004; Aroui et 
al., 2010). This leads to higher intracellular 
drug concentration causing higher toxicity in 
resistant cell lines.
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Figure 6: Toxicity of Gem-R5W3R4 (A), Gem-[RW]6 (B), Gem-[RW5] (C), Gem-[RW]4 (D), Gem-[RW]3 
(E) and Gem to A549 cells. The cells were incubated for 3 days in 10 % FBS with or without peptides 
and analyzed for proliferation by MTT assay. 
 
 
 
In conclusion, the obtained results showed 
that the coupling of gemcitabine to CPPs in-
cluding R5W3R4, [RW]6 and [RW]3 may 
cause the increased antitumor activity of the 
drug. Collectively, the findings in this study 
support the advantages of using CPPs for im-
proving intracellular delivery of drugs into tu-
mor cells as well as their activity. Further-
more, it is possible to overcome gemcitabine 
resistance associated with deficiencies in the 
expression of hENT1 by using CPP strategy. 
In the future work the in vivo effect of the 
gemcitabine-CPP conjugates will be evalu-
ated. Furthermore the investigation of the ef-
fect of CPPs on the other pharmacokinetic pa-
rameters of the drug is worthy. 
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